Corrections Noted in Table 2 of the Study on Ixekizumab and Tirzepatide for Psoriasis in Adults with Overweight or Obesity
-
July 1, 2026
Corrections Noted in Study on Ixekizumab and Tirzepatide for Psoriasis
Background
Psoriasis is a chronic inflammatory skin condition that can be exacerbated by obesity, complicating treatment outcomes. Accurate reporting of clinical trial data is crucial for understanding the efficacy of combination therapies in this patient population.
Data Highlights
No numerical data is presented in the source material.
Key Findings
- Corrections in Table 2 changed baseline PASI reporting from 'mean (SD)' to 'mean (SE)'.
- Metabolic endpoints were also reclassified to 'mean (SE)'.
- 27% of patients on combination therapy achieved both complete skin clearance and at least 10% weight loss at 36 weeks.
- Guidelines recommend considering comorbidities when initiating systemic therapy for psoriasis.
Clinical Implications
Clinicians should be aware of the updated statistical measures in the ixekizumab and tirzepatide study to accurately interpret the findings.
Conclusion
The corrections made to the study's data reporting are essential for ensuring accurate interpretation of the clinical trial results.
Related Resources & Content
- Author(s)/Org, Source, Year -- Title
- conexiant, Combination Therapy Shows Potential in Psoriasis, Obesity
- conexiant, Combo Therapy for Psoriasis With Obesity
- Dermatology and Therapy, 2026 -- Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks
- Frontiers in Endocrinology, Effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity
- S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm – part 1: Treatment recommendations and monitoring
- S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm – part 1: Treatment recommendations and monitoring - PMC
- Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial - PubMed
- Effects of GLP-1 Receptor Agonists on Psoriasis: An “Agent-Specific” Systematic Review of the Literature
Based on findings from:
Errors in Table 2
Jama Dermatology, 2026.
https://jamanetwork.com/journals/jamadermatology/fullarticle/2851675
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
